Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $480.09 USD
Change Today +0.01 / 0.00%
Volume 909.1K
REGN On Other Exchanges
Symbol
Exchange
NASDAQ GS
Munich
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Robert E. Landry Jr.

Chief Financial Officer and Senior Vice President of Finance, Regeneron Pharmaceuticals, Inc.
AgeTotal Calculated CompensationThis person is connected to 0 board members in 0 different organizations across 3 different industries.

50$7,322,956
As of Fiscal Year 2014

Background*

Mr. Robert E. Landry Jr., also known as Bob, Jr. has been Senior Vice President of Finance at Regeneron Pharmaceuticals, Inc since September 2013 and Chief Financial Officer since October 1, 2013. Mr. Landry has responsibility for all financial functions, including Controller's, Treasury, Financial Planning, Tax, and Internal Audit. In his new role, Mr. Goldberg continue to have responsibility for Alliance Management and various administrative functions. He served as ...

Read Full Background

Corporate Headquarters*

777 Old Saw Mill River Road
Tarrytown, New York 10591

United States

Phone: 914-847-7000
Fax: --

Board Members Memberships*

There is no Board Members Memberships data available.

Education*

BBA
University of Notre Dame

Other Affiliations*

Annual Compensation*

Salary$500,000
Bonus$405,000
Total Annual Compensation$905,000

Stock Options*

All Other Compensation$14,818
Exercisable Options20,000
Exercisable Options Value$2,751,000
Unexercisable Options94,000
Unexercisable Options Value$8,613,060
Total Value of Options$11,364,060
Total Number of Options114,000

Total Compensation*

Total Annual Cash Compensation$919,818
Total Short Term Compensation$905,000
Other Long Term Compensation$14,818
Total Calculated Compensation$7,322,956
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
REGN:US $480.09 USD +0.01

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Jean-Jacques Bienaime MBAChief Executive Officer and Director
BioMarin Pharmaceutical Inc.
$916.0K
Robert W. Duggan Chairman and Chief Executive Officer
Pharmacyclics Inc.
--
Jeffrey M. Leiden M.D., Ph.D.Chairman, Chief Executive Officer and President
Vertex Pharmaceuticals Incorporated
$1.0M
Herve Hoppenot Chief Executive Officer, President, Director and Member of Non-Management Stock Option Committee
Incyte Corporation
$2.9M
Jean-Christophe Tellier Chief Executive Officer and Executive Director
UCB S.A.
--
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REGENERON PHARMACEUTICALS, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.